Sun Pharma and SPARC's XELPROS gets USFDA nod

XELPROS will be commercialised in the US by Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceutical Industries Ltd's wholly-owned subsidiary.

Published: 15th September 2018 02:43 PM  |   Last Updated: 15th September 2018 02:43 PM   |  A+A-

Sun Pharma (Photo| Reuters)

By PTI

NEW DELHI: Sun Pharma and its research arm Sun Pharma Advanced Research Company Ltd (SPARC) Friday said the US Food and Drug Administration (USFDA) has approved its new drug application of XELPROS, used to reduce open-angle glaucoma or ocular hypertension.

"This approval is from Sun Pharma's Halol (Gujarat) facility.

Sun Pharma in-licensed XELPROS from SPARC in June 2015 and this approval will trigger a milestone payment to SPARC," Sun Pharma and SPARC said in a joint statement.

SPARC is also eligible for milestone payments and royalties on the commercialisation of XELPROS in the US, it added.

"This approval, coming less than one month following the approval of CEQUA (cyclosporine ophthalmic solution) 0.09 per cent, reaffirms the strength of Sun Pharma's fast-growing Ophthalmics division and its commitment to serving the needs of patients with ocular disorders," Sun Pharma CEO North America Abhay Gandhi said.

XELPROS will be commercialised in the US by Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceutical Industries Ltd's wholly-owned subsidiary.

Shares of Sun Pharma were trading 2.11 per cent higher at Rs 663.55 apiece on BSE.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.